BioViotica

Hypothemycin

CHF 130.00
In stock
BVT-0067-C250250 µgCHF 130.00
BVT-0067-M0011 mgCHF 395.00
More Information
Product Details
Product Type Chemical
Properties
Formula

C19H22O8

MW 378.4
CAS 76958-67-3
Source/Host Chemicals Isolated from Phoma sp.
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white solid.
Solubility Soluble in DMSO or acetone; insoluble in methanol or water.
Identity Determined by 1H-NMR.
Declaration Manufactured by BioViotica.
InChi Key SSNQAUBBJYCSMY-KNTMUCJRSA-N
Smiles COC1=CC(O)=C2C(=C1)[C@H]1O[C@@H]1C[C@H](O)[C@H](O)C(=O)\C=C/C[C@H](C)OC2=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
After reconstitution protect from light at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description
  • Antifungal.
  • Cytotoxic against some tumor cell lines, partly attributed to inhibition of Ras-inducible genes.
  • Inhibits proliferation of mouse and human T cells.
  • Modulates production of cytokines during T cell activation.
  • Facilitates the ubiquitinylation process of cyclin D1.
  • Potent and selective threonine/tyrosine-specific kinase, MEK and other protein kinases inhibitor in both in vitro and in vivo studies.
Product References
  1. Metabolites of pyrenomycetes XIII: Structure of (+) hypothemycin, an antibiotic macrolide from hypomyces trichothecoides: M.S.R. Nair & S.T. Carey; Tetrahedron Lett. 21, 2011 (1980)
  2. Metabolites of pyrenomycetes. XIV: Structure and partial stereochemistry of the antibiotic macrolides hypothemycin and dihydrohypothemycin: M.S.R. Nair, et al.; Tetrahedron 37, 2445 (1981)
  3. Revised structure and stereochemistry of hypothemycin: T. Agatsuma et al.; Chem. Pharm. Bull. 41, 373 (1993)
  4. Antitumor efficacy of hypothemycin, a new Ras-signaling inhibitor: H. Tanaka, et al.; Jpn. J. Cancer Res. 90, 1139 (1999)
  5. Hypothemycin inhibits the proliferative response and modulates the production of cytokines during T cell activation: R. Camacho, et al.; Immunopharmacology 44, 255 (1999)
  6. Resorcylic acid lactones: naturally occurring potent and selective inhibitors of MEK: A. Zhao, et al.; J. Antibiot. 52, 1086 (1999)
  7. Suppression of oncogenic transformation by hypothemycin associated with accelerated cyclin D1 degradation through ubiquitin-proteasome pathway: H. Sonoda, et al.; Life Sci. 65, 381 (1999)
  8. Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides: A. Schirmer, et al.; PNAS 103, 4234 (2006)
  9. Chemistry and biology of resorcylic acid lactones: N. Winssinger, et al.; Chem. Commun. (Camb). 1, 22 (2007), (Review)
  10. The resorcyclic acid lactone Hypothemycin selectively inhibits the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cells: H. Fukazawa, et al.; Biol. Pharm. Bull. 33, 168 (2010)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.